Transfusion by Crowder, Lauren A. et al.
Creutzfeldt-Jakob disease lookback study: 21 years of 
surveillance for transfusion transmission risk
Lauren A. Crowder1, Lawrence B. Schonberger2, Roger Y. Dodd3, and Whitney R. Steele1
1Scientific Affairs, American Red Cross, Rockville, Maryland; 2National Center for Emerging and 
Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, US 
Centers for Disease Control and Prevention, Atlanta, Georgia; 3American Red Cross, Medical 
Office, Gaithersburg, Maryland.
Abstract
BACKGROUND: Transfusion transmission of human prion diseases has been observed for 
variant Creutzfeldt-Jakob disease (vCJD), but not for the classic forms of prion disease (CJD: 
sporadic, genetic, and iatrogenic). Although the presence of prions or misfolded prion proteins in 
blood has been documented in some patients with the most common form of CJD, sporadic CJD, 
no transfusion-transmitted cases of CJD have been recognized. Since 1995, the American Red 
Cross has conducted a lookback study of the recipients of blood products from donors who 
develop CJD to assess the risk of blood-borne CJD transmission in the United States.
STUDY DESIGN AND METHODS: Blood donors subsequently diagnosed with confirmed or 
probable CJD were enrolled and the consignees were asked to identify the recipients of their blood 
products. These donors’ transfusion recipients are traced annually with the National Death Index 
to see if they subsequently die of CJD.
RESULTS: To date, 65 CJD donors have been enrolled along with 826 of their blood recipients. 
These recipients have contributed 3934 person-years of follow-up and no transfusion-transmitted 
cases of CJD have been recognized.
CONCLUSION: From this study, as well as other epidemiologic studies, there is no evidence of 
CJD transfusion transmission; this risk remains theoretical.
Creutzfeldt-Jakob disease (CJD) is a rapidly progressing, invariably fatal, neurodegenerative 
transmissible spongiform encephalopathy. Current research indicates that the infectious 
agent is composed of an abnormally misfolded prion protein.1 The vast majority of CJD 
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cases are thought to occur sporadically, with familial (5%−15%) and iatrogenic (<1%) types 
making up a minority of cases. The pre-1996 described subtypes of sporadic, genetic 
(fCJD), and iatrogenic CJD (iCJD) are commonly referred to as classic CJD1 to distinguish 
them from the variant form of CJD (vCJD) that emerged in the United Kingdom with the 
outbreak of bovine spongiform encephalopathy or “mad cow disease.”
In recent years, between 400 and 500 CJD cases have been reported annually in the United 
States,1 numbers that reflect, in part, increased awareness of this disease and improved 
diagnostic techniques. While a probable diagnosis can be made from clinical symptoms and 
certain tests, a confirmatory diagnosis requires pathologic examination of brain tissue.2,3
Whereas there have been three cases of symptomatic transfusion-transmitted vCJD in the 
United Kingdom, as well as one asymptomatic transmission, to date there have been no 
documented cases of CJD in recipients of blood components from donors who later died 
from classic CJD (CJD donors).4–9 Because prion diseases are always fatal and prion 
infectivity10 or misfolded prion proteins11 have been reported in the blood of four CJD 
patients, epidemiologic studies have been ongoing to determine if disease is transmitted 
person to person through blood component transfusion. The recently updated UK study 
identified no cases in 1194 person-years of survival after transfusion from CJD donors.5 
Although an epidemiologic study in Italy suggested that blood transfusion may be a risk 
factor for later development of CJD,12 this finding has not been confirmed by UK or US 
studies.5,6,9,13 In this report we provide an update on the US lookback study that includes 
data on donors and recipients collected over 21 years.
MATERIALS AND METHODS
In 1995, the American Red Cross (ARC) with support from the US Centers for Disease 
Control and Prevention (CDC) established a lookback study to assess the risk of transfusion 
transmission of CJD. Blood donors with a later diagnosis of CJD are reported to ARC study 
investigators by family members, physicians, health departments, and blood centers. The 
study investigators work with the reporting entity to collect information on the donor that 
allows for prior donation tracing (e.g., full name, date of birth, donation center) and 
establishing evidence of the donor’s diagnosis (confirmed or probable CJD). The blood 
centers where the donor provided donations are contacted to verify the donor’s donation 
history, and if the donor’s status is confirmed, the center is asked to participate. Blood center 
staff identify the consignees for all the donor’s components. The consignees are asked to 
provide demographic information on the recipients of the enrolled donor’s blood using a 
standard form. All recipients with a completed report, and their donors, are enrolled.
Surviving recipients are tracked annually through the National Center for Health Statistics’ 
National Death Index (NDI) for vital status and the multiple causes of death. Because death 
certificate data are filed immediately after death and do not always take into account 
findings from subsequent autopsy, the possibility of miscoding cause of death remains a 
concern. Any identified recipients with neurologic disease code(s) on the death certificate 
are cross-checked by CDC against records from the National Prion Disease Pathology 
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Surveillance Center to verify if the cause of death was later determined to be prion disease 
related. The last search of the NDI identified deaths through December 31, 2014.
Comparison of UK and US studies was carried out using Fisher’s exact statistics; a p value 
of less than 0.05 is considered significant. This study has been approved by ARC and CDC 
Institutional Review Boards.
RESULTS
To date, 65 blood donors who were subsequently diagnosed clinically with CJD by a 
neurologist have been enrolled; 42 (64.6%) had pathologic confirmation of their CJD 
diagnosis. Of the 65 donors, 63 are classified as sporadic CJD, one fCJD (E200K mutation), 
and one iCJD (dura mater transplant). The fCJD donor made one donation of record and 
contributed two transfusable units, one of which had a traceable recipient who received red 
blood cells (RBCs). The iCJD donor made eight donations, contributing 21 transfusable 
units, which had eight traceable recipients (receiving a total of 5 platelet [PLT] units, 2 
plasma units, and one RBC component). The recipient associated with the fCJD case has 
survived 12.73 years. One recipient associated with the iCJD case has survived for 19.48 
years; however, the other seven recipients have a combined survival time of 10.8 person-
years and none were reported to have a neurologic cause of death.
Most (73.8%) of the enrolled donors were male. The mean numbers of donations and 
donated components by the enrolled donors were 21 and 31, respectively (Table 1).
Overall, the 65 donors contributed 1816 total components to the blood supply, from which 
826 (45.5%) had available recipient information. Of the 826 recipients, 572 (69.2%) had 
specified components: 170 PLT units, 291 RBC units, 77 plasma units, 11 whole blood 
units, and 23 other. Of the 826 recipients, 27 had insufficient information to track using the 
NDI, but did contribute to person-time. Annual tracking through the NDI of the vital status 
of the 799 other recipients indicated that through December 2014, a total of 154 were alive 
and 645 were deceased (Table 1).
Given the unknown, yet potentially long incubation period for prion diseases, and the 
likelihood that prion diseases are theoretically more infectious proximal to the onset of 
symptoms, certain recipient groups are of special interest.8 These groups include 264 
recipients who were long-term survivors: that is, they survived for 5 or more years 
posttransfusion (131, 89, and 44 recipients survived 5–9, 10–19, and 201 years, 
respectively), 414 recipients who received blood components donated 60 months or less 
prior to the donor’s CJD diagnosis or symptom onset, and 105 recipients who fit into both of 
those categories. We compared the CJD risk of the third group from this study’s recipients 
with the risk of vCJD among the long-term survivors in the UK study. There were no clinical 
cases of CJD from the 105 recipients in this third group, compared to three such cases of the 
33 long-term survivors in the UK study (Fisher’s exact, p 5 0.013). In addition, one 
asymptomatic vCJD infection was documented among the 33 UK long-term survivors.
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DISCUSSION
This study is assessing the transfusion transmission risk of CJD from specific donors to the 
enrolled recipients. Although we recognize that our enrolled donors and recipients are not 
random samples of the universe of such persons, we believe that for the described relevant 
time intervals (the period between donation and onset of CJD for the donors and the period 
blood recipients were followed after transfusion), our observed best estimate of no 
transfusion transmission risk is likely reasonably unbiased. However, the number of donors 
and recipients and the periods the recipients have been followed may be too small to detect a 
long latent period risk from a rare infectious donor. Because only a limited number of blood 
recipients live for long periods after transfusion,14 com bined with the long incubation 
period for the disease, we are unlikely to see any cases except in recipients with many years 
of posttransfusion survival or when we have acquired enough years of follow-up to see a 
case by chance alone. This study has a large percentage of recipients who lived for 5 years 
or longer posttransfusion (32%) allowing for an increased chance of recognizing a case that 
developed over this time period were it to have occurred.
A limitation of this study is that 35.4% of the enrolled donors did not undergo a brain biopsy 
or autopsy to confirm the neurologist’s clinical diagnosis of CJD. Nevertheless, because 
approximately 90%15 of CJD cases are recognized clinically, we believe that it is reasonable 
to assume that each of these enrolled donors most likely truly had the disease.
The additional years of data presented in this US study update combined with the published 
UK study data on the transfusion transmission risk associated with classic forms of CJD 
include 94 donors, 1037 recipients, and 5128 person-years of observation, with no reported 
cases of CJD in the traced recipients. We believe that these findings further support our 
conclusion that the risk of trans-fusion transmission of classic CJD remains theoretical. 
However, due to ongoing concern that CJD may be transmitted by blood, study enrollment 
and follow-up will continue.
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TABLE 1.
CJD donor case and blood recipient information
Descriptors Blood donors {n = 65} Blood recipients {n = 826}
Number of donations
 Mean 21
 Median 13
Number of components donated
 Total 1816
 Mean 31.0
Mean age {years)
 Symptom onset 60.8
 Transfusion 59.9
 Death 67.7
vital status
 Deceased 645
 Alive, as of December 31, 2014 154
 Not enough information to track annually 27
Person-years of follow-up
 Total 3933.9
 Deceased 1918.6
 Alive, as of December 31, 2014 1919.7
 Not enough information to track annually 95.6
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